Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,594.13
(
0.16%
)
News Focus
News Focus

Replies to post #124067 on Biotech Values

Replies to #124067 on Biotech Values
icon url

DewDiligence

07/28/11 10:26 AM

#124068 RE: ghmm #124067

Nice call in #msg-65643941.

My concern is longer term and if HCV therapies lose the Interferon then what use would be there (in HCV).

The more immediate concern is the shortened average duration of interferon in HCV due to response guided therapy becoming the SoC. This could have an adverse effect on the demand for Promacta that is worse than the proportional reduction in interferon usage.